Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00506805 · ClinicalTrials.gov registry record · Phase 1

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

A Phase 1 study of Cancer, sponsored by Esanex.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
2
Study locations

NCT00506805 is a Phase 1 study of Cancer that has completed, run by Esanex. The registered enrollment target is 44 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00506805, a Phase 1 study of Cancer, has completed, sponsored by Esanex.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
2
Study locations

Study Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Conditions Studied

Cancer

Interventions

  • DRUG SNX-5422

Study Locations (2)

Arizona

  • Pfizer Investigational Site - Scottsdale

Tennessee

  • Pfizer Investigational Site - Nashville

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2007-06
Est. Completion 2010-03
Phase Phase 1

Sponsor

Esanex

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00506805

The ClinicalTrials.gov registry entry for NCT00506805 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which SNX-5422 is the first listed.

NCT00506805 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00506805 about?

NCT00506805 is a clinical study titled "Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies". Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

What is the current status of trial NCT00506805?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2007-06. Estimated completion is 2010-03.

What conditions does trial NCT00506805 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT00506805?

The interventions under investigation include: SNX-5422 (DRUG).

Who is sponsoring clinical trial NCT00506805?

This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00506805 being conducted?

This trial has 2 study locations across Arizona, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.